BioSpace News Archive

Actinium Pharmaceuticals, Inc. announced today that it will be added to the Russell Microcap ® Index at the conclusion of the 2021 Russell indexes annual reconstitution.

assisTek has announced the release of the next generation of its electronic clinical outcome assessment (eCOA) platform.

Cannabics Pharmaceuticals Inc. released today the interim results of its second in-vivo POC study evaluating the efficacy of company’s proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice.

Recently, Pulnovo Medical’s PADN-CFDA clinical trial, has completed all patients enrollment, and will continue to assist each enrollment center to complete the follow-up of enrolled patients, data recovery, data cleaning, etc., and cooperate with the nation’s research center to complete follow up work.

Chronolife, MedTech and service operator for the diagnosis and monitoring of chronic diseases, and the Chugai Pharma France laboratory announce a collaboration to develop a smart textile that will assess the long-term joint health of patients.

There has been augmented focus on personalized medicines and drug discovery utilizing in vitro methods.

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from its Phase 1 clinical trial of DARE-HRT1. DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.

Catalyst Pharmaceuticals, Inc. today announced that it has entered into an exclusive license and supply agreement with DyDo Pharma, Inc. (“DyDo Pharma”) for the development and commercialization of Firdapse.

Backed by Wellspring Capital Management, RAYUS Radiology, after 40 years of success, executes on its vision to further consolidate the radiology industry through acquisitions, development of new centers and employment of key radiologists across the country

Today, Hoth Therapeutics, Inc. , announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.